🇺🇸 FDA
Pipeline program

IXCHIQ

2025/CHU/12

Approved mab active

Quick answer

IXCHIQ for Chikungunya Virus Infection is a Approved program (mab) at ARS Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
ARS Pharmaceuticals
Indication
Chikungunya Virus Infection
Phase
Approved
Modality
mab
Status
active

Clinical trials